BD Launches Revello™ Stent for Enhanced Treatment of Peripheral Artery Disease in Europe

BD Introduces the Revello™ Vascular Covered Stent: A Breakthrough for Peripheral Artery Disease Treatment

Becton, Dickinson and Company (BD) announces the CE marking of its innovative Revello™ Vascular Covered Stent, now approved for use in treating atherosclerotic lesions in the common and external iliac arteries. This significant development arrives at a crucial time as lower-limb peripheral artery disease (PAD), particularly those associated with iliac artery conditions, presents substantial health challenges in the aging population of the European Union. The introduction of the Revello™ Stent signifies BD's continued effort to enhance treatment options within the peripheral vascular landscape, offering healthcare providers a new tool to address this growing health concern.

The Revello™ Stent features a unique self-expanding design that incorporates ultrathin expanded polytetrafluoroethylene (ePTFE) covering, crucial for maintaining arterial patency while conforming to the natural shape of the iliac arteries. Its innovative design also includes compliant ends specifically engineered to minimize trauma to adjacent healthy vessels, addressing a common complication associated with vascular interventions. Rima Alameddine, BD's Worldwide President of Interventional - Peripheral Intervention, highlights that the CE marking signifies a major advancement for physicians dealing with complex iliac artery issues, further establishing BD's commitment to clinical innovation in PAD management.

Precision deployment is crucial in achieving successful outcomes in endovascular procedures, and BD ensures this with the Revello™ Stent through its tri-axial delivery system. This system allows for controlled deployment, featuring an atraumatic tip to ease insertion, a stability sheath for accurate positioning, and intuitive thumbwheel adjustments. Enhanced visualization is provided by tantalum radiopaque markers, which facilitate clear imaging during fluoroscopy, indispensable for navigating complex anatomical scenarios. With various sizes available, the Revello™ Stent presents diversified treatment options, reinforcing BD's commitment to improving patient care for those suffering from the prevalent condition of PAD.

In summary, the Revello™ Vascular Covered Stent not only enhances BD’s peripheral vascular product portfolio but also represents a significant leap towards better clinical outcomes for patients with iliac artery disease across Europe and EEA countries. By prioritizing innovative and patient-centered solutions, BD reaffirms its role as a leader in medical technology and a vital partner in the fight against cardiovascular diseases.

BD continues to address the pressing health issues associated with an increasingly aging populace in Europe. With the launch of the Revello™ Stent, the company aims to significantly improve the quality of life for many individuals affected by PAD. This product emphasizes both BD's dedication to advancing healthcare and the critical role of medical innovation in managing complex vascular conditions.